$MBRX

Moleculin Biotech Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$1.8 -

Extented Hours

VOLUME

200,581

DAY RANGE

1.64 - 1.85

52 WEEK

1.02 - 3.2

Join Discuss about MBRX with like-minded investors

profile
@Math #StockTraders.NET
recently

with $MBRX Atlas bags

116 Replies 15 👍 11 🔥

PR
@proj8 #StockTraders.NET
recently

$MBRX $PFMT watching if pushed for a short entry

48 Replies 12 👍 14 🔥

AN
@andres168 #StockTraders.NET
recently

mbrx foffering

79 Replies 15 👍 6 🔥

WI
@WINTERTRADE #StockTraders.NET
recently

nailed $mbrx

133 Replies 11 👍 8 🔥

profile
@TraderXx #StockTraders.NET
recently

$MBRX man... botched a nice ss opp ffs...

75 Replies 6 👍 8 🔥

profile
@TraderXx #StockTraders.NET
recently

$MBRX doing it

105 Replies 15 👍 7 🔥

profile
@TraderXx #StockTraders.NET
recently

$MBRX starting to remind me of $CBLI

140 Replies 7 👍 7 🔥

Key Metrics

Market Cap

46.30 M

Beta

0.94

Avg. Volume

61.44 K

Shares Outstanding

28.58 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-09

Next Dividend Date

Company Information

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

Website:

HQ: 5300 Memorial Dr Ste 950 Houston, 77007-8274 Texas

Related News